Search clinical trials for: Apatinib mesylate tablet

Total 10316 results

The First Affiliated Hospital of Zhengzhou University

Recruiting

Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC

Esophageal Cancer by AJCC V8 Stage

China
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Anti-PD-1/PD-L1 Antibody Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous Cell

Esophageal Cancer

China
Centre Leon Berard

Recruiting

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST)

Metastatic Gastrointestinal Stromal Tumor | Unresectable Gastrointestinal Stromal Tumor (GIST) | Locally Advanced Gastrointestinal Stromal Tumor (GIST)

France
Samsung Medical Center

Completed

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Stomach Neoplasms

Korea, Republic of
New Mexico Cancer Care Alliance

Withdrawn

A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)

Chronic Myelogenous Leukemia

United States
Fudan University
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients

Metastatic Breast Cancer

China
Lei Li

Completed

First-line Chemotherapy for Recurrent Cervical Cancer

Chemotherapy | Recurrent Cervical Carcinoma | Apatinib | Targeted Therapy | Persistent Advanced Cervical Carcinoma | Vascular Endothelial Growth Factor 2 Inhibitor

China
University of California, Los Angeles

Recruiting

Metformin Treatment in Progressive Multiple Sclerosis

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia

Canada, Italy, United States, United Kingdom, Belgium, Germany, France, Switzerland, Austria, Denmark, Spain, Norway, Sweden, Netherlands, New Zealand, Australia
Sun Yat-sen University

Unknown

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

Non-small Cell Lung Cancer

China
Chengdu Zenitar Biomedical Technology Co., Ltd

Not yet recruiting

A Clinical Study of Puesta Mesylate for Injection in Patients With Solid Tumors

Advanced Solid Tumor

China
New Mexico Cancer Care Alliance

Completed

A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec

Cancer | Leukemia, Other

United States
Peking Union Medical College Hospital

Completed

Study of Apatinib in Patients With Differentiated Thyroid Cancer

Thyroid Cancer

China
Bayer

Completed

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers

Pharmacokinetics

Germany
Ruijin Hospital

Active, not recruiting

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Shoucheng Ma

Unknown

Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients

Colorectal Neoplasms

China
Bausch Health Americas, Inc.

Completed

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

Liver Cirrhosis

United States, Russian Federation
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

PD-L1 Positive Non-small Cell Lung Cancer
Huazhong University of Science and Technology

Unknown

Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer

Gastric Cancer

China
Actavis Inc.

Completed

A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Tablets Under Fed Conditions

Healthy

Canada
Asan Medical Center

Recruiting

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumors

Korea, Republic of
TYK Medicines, Inc

Completed

A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers

Healthy Volunteers

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients

Chronic Myelogenous Leukemia

China
Beijing Hospital
Chinese Society of Clinical Oncology

Recruiting

Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases

Solid Tumor

China
Peking University

Unknown

To Compare the Efficacy of Surgery Followed by Sunitinib With Surgery Followed by Imatinib in GIST Patients With Progression on Imatinib.

GIST

China
Novartis Pharmaceuticals

Completed

Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Chronic Myeloid Leukemia (CML)

Korea, Republic of
Novartis Pharmaceuticals

Completed

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

3rd Line GIST

France, United Kingdom, Belgium, Canada, Spain, Netherlands, Japan, United States
Novartis Pharmaceuticals

Completed

Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2

Neoplasms, Breast

Russian Federation, China, Brazil, Hong Kong, Pakistan, Peru, Thailand, Ukraine
BioGene Pharmaceutical Ltd.

Withdrawn

Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis (ELTA)

Endometriosis | Endometriosis Ovary | Endometriosis, Rectum | Endometriosis Externa

Switzerland
Actavis Inc.

Completed

A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Under Fasting Conditions

Healthy

Canada
First Affiliated Hospital, Sun Yat-Sen University

Completed

The Long-term Efficacy of Imatinib With Hepatic Resection or Other Local Treatment for GIST Liver Metastases

Liver Metastases | GIST, Malignant

China
AstraZeneca

Completed

Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-Therapy for Acute Schizophrenic

Schizophrenia

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Sunshine Lake Pharma Co., Ltd.

Terminated

KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

Advanced HCC

China
Mitsubishi Tanabe Pharma Corporation

Completed

A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

Perennial Allergic Rhinitis

Japan
Centre Leon Berard

Recruiting

Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC (PAXIPEM)

Papillary Renal Cell Carcinoma Type 2

France
AEterna Zentaris
M.D. Anderson Cancer Center

Completed

Ph II Study of Perifosine Plus Gleevec for Patients With GIST

Gastrointestinal Stromal Tumors
University of Bologna
Novartis

Completed

Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day) (CML022)

Chronic Myeloid Leukemia

Italy
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations
GlaxoSmithKline

Completed

Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer

Neoplasms, Breast

Poland, Russian Federation, Latvia, Romania
Eisai Inc.

Completed

Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies

Breast Cancer

United States
Eisai Co., Ltd.

Completed

Study of E7389 for Advanced or Metastatic Breast Cancer

Breast Cancer

Japan
University of Cologne
Sanofi; Novartis; Roche Pharma AG

Completed

First-line Therapy of Stage IV Colorectal Cancer

Stage IV Colorectal Cancer

Germany
Stallergenes Greer

Completed

Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma

Asthma | House Dust Mite Allergy

France, Germany, Poland
Calgent Biotechnology Co., Ltd

Completed

Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

Resistant or Refractory Solid Tumors

United States, Taiwan
Eisai Korea Inc.

Completed

Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer (ESKIMO)

Breast Cancer | Breast Neoplasms

Korea, Republic of
Eisai Inc.

Approved for marketing

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

Metastatic Breast Cancer

Canada, Belgium, France
Merz Pharmaceuticals GmbH

Terminated

Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus (OLLTT)

Subjective Tinnitus

United States, United Kingdom, Poland, Austria, Belgium, Brazil, Czech Republic, France, Germany, Mexico, Netherlands, Portugal, South Africa, Spain
Pathway Therapeutics, Inc.

Completed

Study of PWT33597 Mesylate in Subjects With Advanced Malignancies

Malignancies

United States
Merz Pharmaceuticals GmbH

Terminated

Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

Multiple Sclerosis | Nystagmus, Congenital | Nystagmus, Acquired

United Kingdom

3

Subscribe